Pulmonary Fibrosis

HomePatientsLung Disease Week at the ATS2011Pulmonary Fibrosis ▶ Webinar: “New Directions for IPF Treatments: Understanding the Basis for Current Clinical Trials"
Webinar: “New Directions for IPF Treatments: Understanding the Basis for Current Clinical Trials"

As part of Pulmonary Fibrosis Week at the ATS, and in conjunction with PAR partner the Coalition for Pulmonary Fibrosis (CPF) the ATS presented a live webinar on Wednesday, September 14, 2011 at 2:00 pm ET. The webinar was hosted by Andrew Tager, MD.

Dr. Tager is Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital. Assistant Physician, Pulmonary and Critical Unit, Massachusetts General Hospital, and Assistant Professor of Medicine, Harvard Medical School

He has done investigations of lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) in the pathogenesis of pulmonary fibrosis in idiopathic pulmonary fibrosis and the acute respiratory distress syndrome, and of dermal fibrosis in scleroderma.